Hill-Rom (HRC) Given Buy Rating at KeyCorp

KeyCorp restated their buy rating on shares of Hill-Rom (NYSE:HRC) in a research note released on Thursday morning. They currently have a $94.00 target price on the medical technology company’s stock.

HRC has been the subject of a number of other research reports. Zacks Investment Research raised Hill-Rom from a sell rating to a hold rating in a research note on Monday, September 18th. ValuEngine lowered Hill-Rom from a buy rating to a hold rating in a research note on Friday, December 1st. Barclays boosted their target price on Hill-Rom from $86.00 to $90.00 and gave the company an overweight rating in a research note on Monday, November 6th. Bank of America reissued a hold rating on shares of Hill-Rom in a research note on Wednesday, November 22nd. Finally, Stifel Nicolaus boosted their target price on Hill-Rom from $84.00 to $85.00 and gave the company a buy rating in a research note on Monday, November 6th. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of Buy and a consensus target price of $90.29.

Shares of Hill-Rom (HRC) opened at $85.05 on Thursday. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.34 and a current ratio of 1.77. Hill-Rom has a 52 week low of $55.04 and a 52 week high of $85.74. The stock has a market capitalization of $5,620.00, a PE ratio of 42.74, a price-to-earnings-growth ratio of 1.80 and a beta of 1.19.

Hill-Rom (NYSE:HRC) last issued its quarterly earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.27 by $0.05. Hill-Rom had a return on equity of 20.27% and a net margin of 4.87%. The firm had revenue of $738.30 million during the quarter, compared to analyst estimates of $731.10 million. During the same quarter in the previous year, the company posted $1.18 earnings per share. The company’s revenue was up 4.6% compared to the same quarter last year. sell-side analysts forecast that Hill-Rom will post 4.26 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 15th will be given a dividend of $0.18 per share. This represents a $0.72 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date is Thursday, December 14th. Hill-Rom’s payout ratio is 36.18%.

In other Hill-Rom news, CEO John J. Greisch sold 125,241 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $82.59, for a total transaction of $10,343,654.19. Following the completion of the transaction, the chief executive officer now owns 280,851 shares of the company’s stock, valued at approximately $23,195,484.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Paul Sherwood Johnson sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $82.99, for a total value of $82,990.00. Following the transaction, the senior vice president now owns 1,066 shares in the company, valued at approximately $88,467.34. The disclosure for this sale can be found here. Insiders have sold a total of 226,241 shares of company stock valued at $18,708,644 in the last ninety days. 2.20% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the business. Stifel Financial Corp grew its holdings in shares of Hill-Rom by 0.5% during the 2nd quarter. Stifel Financial Corp now owns 4,379 shares of the medical technology company’s stock worth $349,000 after acquiring an additional 23 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in shares of Hill-Rom by 0.5% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,734 shares of the medical technology company’s stock worth $695,000 after acquiring an additional 46 shares during the period. Utah Retirement Systems grew its holdings in shares of Hill-Rom by 0.8% during the 2nd quarter. Utah Retirement Systems now owns 12,013 shares of the medical technology company’s stock worth $956,000 after acquiring an additional 100 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Hill-Rom by 10.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock worth $175,000 after acquiring an additional 204 shares during the period. Finally, ETRADE Capital Management LLC grew its holdings in shares of Hill-Rom by 4.6% during the 2nd quarter. ETRADE Capital Management LLC now owns 6,940 shares of the medical technology company’s stock worth $552,000 after acquiring an additional 303 shares during the period. Hedge funds and other institutional investors own 82.33% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/12/25/hill-rom-hrc-given-buy-rating-at-keycorp.html.

About Hill-Rom

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Analyst Recommendations for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit